We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Humoral response to two doses of BNT162b2 vaccination in people with HIV.
- Authors
Heftdal, Line Dam; Knudsen, Andreas Dehlbæk; Hamm, Sebastian Rask; Hansen, Cecilie Bo; Møller, Dina Leth; Pries‐Heje, Mia; Fogh, Kamille; Hasselbalch, Rasmus Bo; Jarlhelt, Ida; Pérez‐Alós, Laura; Hilsted, Linda Maria; Ostrowski, Sisse Rye; Gerstoft, Jan; Grønbæk, Kirsten; Bundgaard, Henning; Iversen, Kasper; Garred, Peter; Nielsen, Susanne Dam
- Abstract
Background: People with HIV (PWH) are at increased risk of severe COVID‐19. We aimed to determine humoral responses in PWH and controls who received two doses of BNT162b2. Methods: In 269 PWH and 538 age‐matched controls, we measured IgG and neutralizing antibodies specific for the receptor‐binding domain of SARS‐CoV‐2 at baseline, 3 weeks and 2 months after the first dose of BNT162b2. Results: IgG antibodies increased from baseline to 3 weeks and from 3 weeks to 2 months in both groups, but the concentrations of IgG antibodies were lower in PWH than that in controls at 3 weeks and 2 months (p = 0.025 and <0.001), respectively. The IgG titres in PWH with a humoral response at 2 months were 77.9% (95% confidence interval [62.5%–97.0%], age‐ and sex‐adjusted p = 0.027) of controls. Conclusions: Reduced IgG antibody response to vaccination with BNT162b2 was found in PWH, and thus increased awareness of breakthrough infections in PWH is needed.
- Subjects
AIDS vaccines; HUMORAL immunity; COVID-19 vaccines; HIV-positive persons; ANTIBODY formation
- Publication
Journal of Internal Medicine, 2022, Vol 291, Issue 4, p513
- ISSN
0954-6820
- Publication type
Article
- DOI
10.1111/joim.13419